Liste publications Plateforme recherche translationnelle

Transcription

Liste publications Plateforme recherche translationnelle
Plateforme de recherche translationnelle
Centre Léon Bérard
Liste des publications :
• Equipe Dr COMBARET :
Combaret V, Bréjon S, Iacono I, Schleiermacher G, Pierron G, Ribeiro A,Bergeron C,
Marabelle A, Puisieux A. Determination of 17q gain in patients with neuroblastoma by
analysis of circulating DNA. Pediatr Blood Cancer. 2011 May;56(5):757-61. doi:
10.1002/pbc.22816. Epub 2011 Jan 11.
Ambros IM, Brunner B, Aigner G, Bedwell C, Beiske K, Bénard J, Bown N,Combaret V,
Couturier J, Defferrari R, Gross N, Jeison M, Lunec J, Marques B, Martinsson T, Mazzocco K,
Noguera R, Schleiermacher G, Speleman F, Stallings R, Tonini GP, Tweddle DA, Valent A,
Vicha A, Roy NV, Villamon E, Ziegler A, Preuner S, Drobics M, Ladenstein R, Amann G, Schuit
RJ, Pötschger U, Ambros PF. A multilocus technique for risk evaluation of patients with
neuroblastoma. Clin Cancer Res. 2011 Feb 15;17(4):792-804.
Mazot P, Cazes A, Boutterin MC, Figueiredo A, Raynal V, Combaret V, Hallberg B, Palmer RH,
Delattre O, Janoueix-Lerosey I, Vigny M. The constitutive activity of the ALK mutated at
positions F1174 or R1275 impairs receptor trafficking.Oncogene. 2011 Jan 17.
Chargui J, Combaret V, Scaglione V, Iacono I, Péri V, Valteau-Couanet D,Dubrel M, Angevin E,
Puisieux A, Romagne F, Bergeron C. Bromohydrin pyrophosphate-stimulated
Vgamma9delta2 T cells expanded ex vivo from patients with poor-prognosis neuroblastoma
lyse autologous primary tumor cells. J Immunother. 2010 Jul-Aug;33(6):591-8.
Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, Klijanienko J, Couturier J,Pierron G, Mosseri
V, Valent A, Auger N, Plantaz D, Rubie H, Valteau-Couanet D, Bourdeaut F, Combaret V,
Bergeron C, Michon J, Delattre O. Accumulation of segmental alterations determines
progression in neuroblastoma. J Clin Oncol. 2010 Jul 1;28(19):3122-30. Epub 2010 Jun 1.
Bouzas-Rodriguez J, Cabrera JR, Delloye-Bourgeois C, Ichim G, Delcros JG,Raquin MA,
Rousseau R, Combaret V, Bénard J, Tauszig-Delamasure S, Mehlen P. Neurotrophin-3
production promotes human neuroblastoma cell survival by inhibiting TrkC-induced
apoptosis. J Clin Invest. 2010 Mar 1;120(3):850-8. doi:10.1172/JCI41013. Epub 2010 Feb 15.
Hoebeeck J, De Wilde B, Michels E, Combaret V, Yigit N, De Smet E, Van Roy N, Stanbridge E,
Ru N, Laureys G, De Paepe A, Speleman F, Vandesompele J. Chromosome 3p microsatellite
allelotyping in neuroblastoma: a report on the technical hurdles. Cancer Invest. 2009
Oct;27(8):857-68.
Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, Swerts K, Bravo
S, Scaruffi P, Tonini GP, De Bernardi B, Noguera R, Piqueras M, Cañete A, Castel V, JanoueixListe des publications – Laboratoire de recherche translationnelle – Mars 2011
Lerosey I, Delattre O, Schleiermacher G, Michon J, Combaret V, Fischer M, Oberthuer A,
Ambros PF, Beiske K, Bénard J, Marques B, Rubie H, Kohler J, Pötschger U, Ladenstein R,
Hogarty MD, McGrady P, London WB, Laureys G, Speleman F, Vandesompele J. Predicting
outcomes for children with neuroblastoma using a multigene-expression signature: a
retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 2009 Jul;10(7):663-71. Epub 2009 Jun
8.
Delloye-Bourgeois C, Fitamant J, Paradisi A, Cappellen D, Douc-Rasy S, Raquin MA, Stupack
D, Nakagawara A, Rousseau R, Combaret V, Puisieux A, Valteau-Couanet D, Bénard J, Bernet
A, Mehlen P. Netrin-1 acts as a survival factor for aggressive neuroblastoma. J Exp Med. 2009
Apr 13;206(4):833-47. Epub 2009 Apr 6.
Combaret V, Hogarty MD, London WB, McGrady P, Iacono I, Brejon S, Swerts K,Noguera R,
Gross N, Rousseau R, Puisieux A. Influence of neuroblastoma stage on serum-based
detection of MYCN amplification. Pediatr Blood Cancer. 2009 Sep;53(3):329-31.
Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, Vermeulen
J, Couturier J, Peuchmaur M, Valent A, Plantaz D, Rubie H, Valteau-Couanet D, Thomas C,
Combaret V, Rousseau R, Eggert A, Michon J, Speleman F, Delattre O. Overall genomic
pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009 Mar 1;27(7):1026-33.
Epub 2009 Jan 26.
Janoueix-Lerosey I, Lequin D, Brugières L, Ribeiro A, de Pontual L, Combaret V, Raynal V,
Puisieux A, Schleiermacher G, Pierron G, Valteau-Couanet D, Frebourg T, Michon J, Lyonnet
S, Amiel J, Delattre O. Somatic and germline activating mutations of the ALK kinase receptor
in neuroblastoma. Nature. 2008 Oct 16;455(7215):967-70.
Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, Hoyoux C, Laureys G, De
Paepe A, Speleman F, Vandesompele J. Aberrant methylation of candidate tumor suppressor
genes in neuroblastoma. Cancer Lett. 2009 Jan 18;273(2):336-46. Epub 2008 Sep 25.
Combaret V, Boyault S, Iacono I, Brejon S, Rousseau R, Puisieux A. Effect of bortezomib on
human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity. Mol
Cancer. 2008 Jun 5;7:50.
Vandesompele J, Michels E, De Preter K, Menten B, Schramm A, Eggert A, Ambros PF,
Combaret V, Francotte N, Antonacci F, De Paepe A, Laureys G, Speleman F, Van Roy N.
Identification of 2 putative critical segments of 17q gain in neuroblastoma through
integrative genomics. Int J Cancer. 2008 Mar 1;122(5):1177-82.
Michels E, Vandesompele J, De Preter K, Hoebeeck J, Vermeulen J, Schramm A,Molenaar JJ,
Menten B, Marques B, Stallings RL, Combaret V, Devalck C, De Paepe A, Versteeg R, Eggert A,
Laureys G, Van Roy N, Speleman F. ArrayCGH-based classification of neuroblastoma into
genomic subgroups. Genes Chromosomes Cancer. 2007 Dec;46(12):1098-108.
Liste des publications – Laboratoire de recherche translationnelle – Mars 2011
Michalowski MB, de Fraipont F, Plantaz D, Michelland S, Combaret V, Favrot MC.
Methylation of tumor-suppressor genes in neuroblastoma: The RASSF1A gene is almost
always methylated in primary tumors. Pediatr Blood Cancer. 2008 Jan;50(1):29-32.
Rousseau R, Combaret V, Yvon E, Schell M, Philip I, Puisieux A, Frappaz D, Philip T, Bergeron
C. [Immunotherapy of poor-prognosis neuroblastoma in children:from bench to bedside].
Bull Cancer. 2006 Feb 1;93(2):153-61. Review.
Combaret V, Bergeron C, Noguera R, Iacono I, Puisieux A. Circulating MYCN DNA predicts
MYCN-amplification in neuroblastoma. J Clin Oncol. 2005 Dec
1;23(34):8919-20; author reply 8920.
Krause A, Combaret V, Iacono I, Lacroix B, Compagnon C, Bergeron C, Valsesia-Wittmann S,
Leissner P, Mougin B, Puisieux A. Genome-wide analysis of gene expression in
neuroblastomas detected by mass screening. Cancer Lett. 2005 Jul 8;225(1):111-20. Epub
2004 Dec 8.
Combaret V, Bergeron C, Bréjon S, Iacono I, Perol D, Négrier S, Puisieux A.Protein chip array
profiling analysis of sera from neuroblastoma patients. Cancer Lett. 2005 Oct 18;228(1-2):916. Review.
De Preter K, Speleman F, Combaret V, Lunec J, Board J, Pearson A, De Paepe A, Van Roy N,
Laureys G, Vandesompele J. No evidence for correlation of DDX1 gene amplification with
improved survival probability in patients with MYCN-amplified neuroblastomas. J Clin Oncol.
2005 May 1;23(13):3167-8; author reply 3168-70.
Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, Brinkschmidt C,
Christiansen H, Combaret V, Lastowska M, Nicholson J, O'Meara A, Plantaz D, Stallings R,
Brichard B, Van den Broecke C, De Bie S, De Paepe A, Laureys G, Speleman F. Unequivocal
delineation of clinicogenetic subgroups and development of a new model for improved
outcome prediction in neuroblastoma. J Clin Oncol. 2005 Apr 1;23(10):2280-99.
Schleiermacher G, Bourdeaut F, Combaret V, Picrron G, Raynal V, Aurias A,Ribeiro A,
Janoueix-Lerosey I, Delattre O. Stepwise occurrence of a complex unbalanced translocation
in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q
gain. Oncogene. 2005 May 5;24(20):3377-84.
Liste des publications – Laboratoire de recherche translationnelle – Mars 2011
• Equipe Dr ALBERTI
Gougelet A, Perez J, Pissaloux D,Besse A, Duc A, Decouvelaere AV, Ranchere-Vince D, Blay JY,
and Alberti L miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and
Treatment of Sarcomas,
Volume 2011 (2011), Article ID 460650, 13 pages
Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY, Alberti L. Micro-RNA
profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 2010 Oct
14.
Ducimetière F, Lurkin A, Ranchère-Vince D, Decouvelaere AV, Isaac S,
Claret-Tournier C, Suignard Y, Salameire D, Cellier D, Alberti L, Bringuier PP,Blay JY, RayCoquard I. [Incidence rate, epidemiology of sarcoma and molecular biology. Preliminary
results from EMS study in the Rhône-Alpes region]. Bull Cancer. 2010 Jun;97(6):629-41.
Cassier P, Pissaloux D, Alberti L, Ray-Coquard I, Blay JY. [Targeted treatment of rare
connective tissue tumors and sarcomas]. Bull Cancer. 2010 Jun;97(6):693-700
Gougelet A, Mansuy A, Blay JY, Alberti L, Vermot-Desroches C. Lymphoma and myeloma cell
resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6
antibody. PLoS One. 2009 Nov 30;4 (11)
Fayette J, Boyle H, Chabaud S, Favier B, Engel C, Cassier P, Thiesse P, Méeus P, Sunyach MP,
Vaz G, Ray-Coquard I, Ranchère D, Decouvelaere AV, Alberti L, Pérol D, Blay JY. Efficacy of
trabectedin for advanced sarcomas in clinical trials versus compassionate use programs:
analysis of 92 patients treated in a single institution. Anticancer Drugs. 2010 Jan;21(1):113-9.
Cassier PA, Dufresne A, Arifi S, El Sayadi H, Ray-Coquard I, Bringuier PP,Scoazec JY, Alberti L,
Blay JY. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and
sunitinib. Curr Gastroenterol Rep. 2008 Dec;10(6):555-61. Review.
Cassier PA, Dufresne A, El Sayadi H, Pissaloux D, Alberti L, Decouvelaere AV, Ranchere D,
Ray-Coquard I, Blay JY. [Targeted therapy of sarcomas]. Bull Cancer. 2008 Oct;95(10):963-74.
Cassier PA, Dufresne A, Arifi S, El Sayadi H, Labidi I, Ray-Coquard I, Tabone S, Méeus P,
Ranchère D, Sunyach MP, Decouvelaere AV, Alberti L, Blay JY. Imatinib mesilate for the
treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother. 2008
May;9(7):1211-22. Review.
Tabone-Eglinger S, Subra F, El Sayadi H, Alberti L, Tabone E, Michot JP, Théou-Anton N,
Lemoine A, Blay JY, Emile JF. KIT mutations induce intracellular retention and activation of an
immature form of the KIT protein in gastrointestinal stromal tumors. Clin Cancer Res. 2008
Apr 15;14(8):2285-94.
Liste des publications – Laboratoire de recherche translationnelle – Mars 2011
Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere
AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P. [Imatinib and solid tumours]. Bull Cancer.
2008 Jan;95(1):99-106. Review.
Cassier PA, Dufresne A, Fayette J, Alberti L, Ranchere D, Ray-Coquard I, Blay JY. Emerging
drugs for the treatment of soft tissue sarcomas. Expert Opin Emerg Drugs. 2007
Mar;12(1):139-53. Review.
Fayette J, Coquard IR, Alberti L, Boyle H, Méeus P, Decouvelaere AV, Thiesse P, Sunyach MP,
Ranchère D, Blay JY. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin
Oncol. 2006 Jul;18(4):347-53. Review.
13: Fayette J, Coquard IR, Alberti L, Ranchère D, Boyle H, Blay JY. ET-743: a novel agent with
activity in soft tissue sarcomas. Oncologist. 2005 Nov-Dec;10(10):827-32. Review.
Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies.Bull Cancer. 2005
Feb;92
• Equipe Dr WANG
En cours de publication
Liste des publications – Laboratoire de recherche translationnelle – Mars 2011

Documents pareils